Study synopsis
BRONCHOPULMONARY DYSPLASIA (BPD)
The PLUSS trial is a multicenter, two-arm, parallel, double-blind, randomized controlled trial, enrolling at least 1060 extremely preterm infants in 21 participating hospitals across four countries (Australia, New Zealand, Canada, and Singapore). Enrolment commenced in January 2018 and was completed in March 2023. The trial is investigating whether intratracheal budesonide (a corticosteroid) combined with surfactant, compared with surfactant alone, will increase survival free of bronchopulmonary dysplasia (BPD) in extremely preterm infants.Full details of the background to the trial and its design are presented in the published protocol [